Recipharm strengthens its competitiveness by focusing on leading, core CDMO segments

2 April 2024, Stockholm – Today, Recipharm announced that Blue Wolf Capital Partners, a US-based private equity firm, has committed, subject to regulatory clearances, to acquire seven of its sites: Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development in Sweden; Pessac in France; and Parets in Spain. This announcement is a significant milestone for Recipharm colleagues at those sites, as they form a new organisation under the leadership of Peter Kruger, Group Managing Director.

This divestment commitment represents a positive milestone for Recipharm, and, combined with the spin out of ADS, enhances Recipharm’s agility, enabling greater focus on its customers' needs.

Greg Behar, Recipharm’s CEO, said: “This strategic move underscores our vision to be the CDMO of choice for our customers and patients. The consolidation of our sites network gives a sharp focus to our oral solid dosage activity on New Chemical Entities (NCEs), medium to high potency and on-patent drugs, supporting our aspiration to being the number 1 oral solid dosage CDMO in Europe. In the sterile fill and finish segment, we maintain our focus on building our leadership in lyophilisation and pre-filled syringes (PFS). In Biologics, ReciBioPharm continues to build our differentiated presence in nucleic acids and viruses, with the ambition to strengthen our leading position in nucleic acids, in microbiome and in viruses.

“Operationally, this announcement bolsters our commitment to being a reliable provider of development and manufacturing services, consistently delivered with certainty.

“I wish all colleagues at those seven sites best of luck for the future.”

The transaction is expected to close in Q4 2024, subject to customary regulatory approvals.

Recipharm was advised by William Blair (M&A), Roschier (Legal), PwC (Financial and Tax), IQVIA (Commercial) and ERM (Environmental, Social and Governance).